Methylene Chloride Comment.

cost–benefit analysis regulation toxic chemicals worker protections

Journal

New solutions : a journal of environmental and occupational health policy : NS
ISSN: 1541-3772
Titre abrégé: New Solut
Pays: United States
ID NLM: 9100937

Informations de publication

Date de publication:
Nov 2023
Historique:
medline: 6 11 2023
pubmed: 30 8 2023
entrez: 30 8 2023
Statut: ppublish

Résumé

Last May 2023, the U.S. Environmental Protection Agency (EPA) published a proposed rule to restrict the production and use of a dangerous chemical called methylene chloride pursuant to its authority under the Toxic Substance Control Act-the first such measure since Congress significantly overhauled that law in 2016. Methylene chloride presents a variety of health and safety risks, particularly for workers in industries in which the chemical is still widely used. In support of the proposed rule, the EPA prepared a document called a cost-benefit analysis, which purports to evaluate the rule by calculating its net benefits-that is, the rule's likely benefits over and above its likely costs. Cost-benefit analysis has been the subject of substantial criticism in recent decades, and the Biden administration is pursuing significant reforms for how these analyses are performed. Together with my colleague Dr. Federico Holm, I submitted comments to the EPA criticizing the cost-benefit analysis for the proposed methylene chloride rule. In these comments, we criticize the agency for continuing to employ an overly formalistic approach to cost-benefit analysis, which both systematically undervalues the benefits of regulations and ignores impact issues like worker justice. We also criticize several specific aspects of the agency's analytical methodology, including its failure to follow the proposed reforms now being developed by the Biden administration.

Identifiants

pubmed: 37644913
doi: 10.1177/10482911231198148
doi:

Substances chimiques

Methylene Chloride 588X2YUY0A

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

174-184

Déclaration de conflit d'intérêts

Declaration of Conflicting InterestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Auteurs

James Goodwin (J)

Center for Progressive Reform, Washington, District of Columbia, USA.

Federico Holm (F)

Center for Progressive Reform, Washington, District of Columbia, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH